Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $78.00

Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $78.00.

A number of brokerages have recently weighed in on LNTH. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Truist Financial upped their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Mizuho raised their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th.

Lantheus Price Performance

LNTH opened at $67.81 on Friday. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 28.49 and a beta of -0.11. The firm’s fifty day moving average price is $63.83 and its two-hundred day moving average price is $60.14.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. During the same period last year, the firm earned $1.70 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several hedge funds have recently added to or reduced their stakes in the stock. Martin Capital Advisors LLP increased its stake in shares of Lantheus by 9.2% during the 4th quarter. Martin Capital Advisors LLP now owns 14,166 shares of the medical equipment provider’s stock worth $943,000 after purchasing an additional 1,188 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in Lantheus by 6.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 32,596 shares of the medical equipment provider’s stock valued at $2,169,000 after purchasing an additional 1,856 shares during the last quarter. Blue Trust Inc. grew its holdings in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the period. Finally, Three Seasons Wealth LLC increased its position in Lantheus by 41.0% in the fourth quarter. Three Seasons Wealth LLC now owns 9,602 shares of the medical equipment provider’s stock worth $639,000 after buying an additional 2,794 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.